Related Experiment Videos

Bactericidal activity of imipenem compared to erythromycin against intracellular Legionella pneumophila

J A Ramirez1, J T Summersgill, R D Miller

  • 1Louisville Veterans Affairs Medical Centre, KY.

Drugs Under Experimental and Clinical Research
|January 1, 1992
PubMed

Insights

Imipenem shows promise for treating nosocomial pneumonia, including Legionella infections. Further research is needed to confirm its efficacy against intracellular bacteria in severe pneumonia cases.

Area of Science:

  • Infectious Diseases
  • Bacteriology
  • Critical Care Medicine

Background:

  • Nosocomial pneumonia is a leading cause of death, with mortality rates from 30-70%.
  • Imipenem exhibits broad-spectrum in vitro activity against common nosocomial pneumonia pathogens.
  • Legionella species are increasingly recognized as significant nosocomial pathogens, potentially causing up to 30% of cases.

Purpose of the Study:

  • To evaluate the efficacy of imipenem against intracellular Legionella species.
  • To assess imipenem's potential as an empirical therapy for severe nosocomial pneumonias, including Legionella.

Main Methods:

  • In vitro testing of imipenem's bactericidal activity against Legionella.
  • Assessment of imipenem's efficacy against intracellular Legionellae (specific methods not detailed in abstract).

Main Results:

  • Imipenem demonstrated bactericidal activity against Legionella in vitro.
  • Efficacy against intracellular Legionellae was not previously established.

Conclusions:

  • Imipenem possesses in vitro activity against Legionella.
  • Further studies are warranted to determine imipenem's clinical effectiveness against intracellular Legionella in nosocomial pneumonia.

Related Concept Videos